Relief Therapeutics Holding SA · ISIN: CH0100191136 · EQS - Company News

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024

Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 18.09.2024 / 07:00 CET/CEST Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024   GENEVA (SEPT. 18, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company...

SIX:RLF Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Relief Therapeutics Holding SA

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
18 September 2024 07:00AM
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
CH0100191136
Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 18.09.2024 / 07:00 CET/CEST Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October ...
Relief Therapeutics Holding SA
About the publication
02 September 2024 07:00AM
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
CH0100191136
Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 02.09.2024 / 07:00 CET/CEST Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 GENEVA (SEPT. 2, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RL...
Relief Therapeutics Holding SA
About the publication
30 August 2024 07:00AM
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
CH0100191136
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming weeks RLF-OD032 pilot PK study progresses with potential NDA filing by mid- to late 2025 Streamlined operations and CHF 15.1 million cash reserves expected to p...
Relief Therapeutics Holding SA
About the publication
30 May 2024 07:00AM
Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders
CH0100191136
Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders GENEVA (MAY 30, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the Annual General Meeting (AGM) o...
Relief Therapeutics Holding SA
About the publication
30 April 2024 07:00AM
Relief Therapeutics has published its Annual Report
CH0100191136
Relief Therapeutics has published its Annual Report GENEVA (APR. 30, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its Annual Report 2023 and provided a corporate update....
Relief Therapeutics Holding SA
About the publication
27 March 2024 07:00AM
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
CH0100191136
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General MeetingRelief Therapeutics Calls Extraordinary General Meeting Anticipated Board of Directors Overhaul GENEVA (MAR. 27, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innova...
Relief Therapeutics Holding SA
About the publication
22 March 2024 07:00AM
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
CH0100191136
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE® GENEVA (MAR. 22, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare...
Relief Therapeutics Holding SA
About the publication
28 February 2024 06:45AM
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
CH0100191136
Relief Therapeutics Renews CHF 50 million Share Subscription Facility 3-year CHF 50 million capital commitment from GEM Relief advances strategic transformation GENEVA (FEB. 28, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment ...
Relief Therapeutics Holding SA
About the publication
05 December 2023 07:00AM
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
CH0100191136
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth GENEVA (DEC. 5, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet ...
Relief Therapeutics Holding SA
About the publication
22 November 2023 08:40AM
Relief Therapeutics Announces CEO Transition
CH0100191136
Relief Therapeutics Announces CEO Transition GENEVA (NOV. 22, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that its current chief executive officer (CEO)...
Relief Therapeutics Holding SA
About the publication
10 October 2023 07:00AM
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone
CH0100191136
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone GENEVA (OCT. 10, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to deliverin...
Relief Therapeutics Holding SA
About the publication
15 September 2023 07:00AM
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
CH0100191136
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update GENEVA (SEPT. 15, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today reported ...
Relief Therapeutics Holding SA
About the publication
01 September 2023 07:45AM
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
CH0100191136
Relief Therapeutics Holding SA / Key word(s): Conference Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference 01.09.2023 / 07:45 CET/CEST Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference GENEVA (SEPT. 1, 2023) – ...
Relief Therapeutics Holding SA
About the publication
30 August 2023 10:20PM
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer Therapeutics
CH0100191136
 Ad hoc announcement pursuant to Art. 53 LR   Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer TherapeuticsAcer Therapeutics buys Relief Therapeutics’ stake in OLPRUVA™ worldwide, excluding geographical Europe, providing an upfront payment of $10 million in cash to Relief Therapeutics with...
Relief Therapeutics Holding SA
About the publication
19 July 2023 07:30AM
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health
CH0100191136
Relief Therapeutics Holding SA / Key word(s): Agreement/Product Launch Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health 19.07.2023 / 07:30 CET/CEST Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with...
Relief Therapeutics Holding SA
About the publication
19 July 2023 07:30AM
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health
CH0100191136
Relief Therapeutics Holding SA / Key word(s): Agreement/Product Launch Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health 19.07.2023 / 07:30 CET/CEST Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with...
Relief Therapeutics Holding SA
About the publication
23 June 2023 07:15AM
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East
CH0100191136
Ad hoc announcement pursuant to Art. 53 LR   Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East     GENEVA and DUBAI, United Arab Emirates (June 23, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or t...
Relief Therapeutics Holding SA
About the publication
23 June 2023 07:15AM
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East
CH0100191136
Ad hoc announcement pursuant to Art. 53 LR   Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East     GENEVA and DUBAI, United Arab Emirates (June 23, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or t...
Relief Therapeutics Holding SA
About the publication
23 June 2023 07:00AM
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
CH0100191136
Ad hoc announcement pursuant to Art. 53 LR RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement GENEVA (June 23, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the pote...
Relief Therapeutics Holding SA
About the publication
23 June 2023 07:00AM
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
CH0100191136
Ad hoc announcement pursuant to Art. 53 LR RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement GENEVA (June 23, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the pote...
Relief Therapeutics Holding SA
About the publication
20 June 2023 10:57AM
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
CH0100191136
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders GENEVA (June 20, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to ...
Relief Therapeutics Holding SA
About the publication
20 June 2023 10:57AM
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
CH0100191136
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders GENEVA (June 20, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to ...
Relief Therapeutics Holding SA
About the publication
16 June 2023 07:00AM
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
CH0100191136
Ad hoc announcement pursuant to Art. 53 LR   RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement GENEVA (June 16, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFFD, RLFTD) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for t...
Relief Therapeutics Holding SA
About the publication
16 June 2023 07:00AM
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
CH0100191136
Ad hoc announcement pursuant to Art. 53 LR   RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement GENEVA (June 16, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFFD, RLFTD) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for t...
Relief Therapeutics Holding SA
About the publication
26 May 2023 07:00AM
RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders
CH0100191136
RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders GENEVA (May 26, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFFD, RLFTD) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to be...
Relief Therapeutics Holding SA
About the publication
26 May 2023 07:00AM
RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders
CH0100191136
RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders GENEVA (May 26, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFFD, RLFTD) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to be...
Relief Therapeutics Holding SA
About the publication
15 May 2023 07:00AM
Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory
CH0100191136
Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory 15.05.2023 / 07:00 CET/CEST Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laborato...
Relief Therapeutics Holding SA
About the publication
15 May 2023 07:00AM
Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory
CH0100191136
Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory 15.05.2023 / 07:00 CET/CEST Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laborato...
Relief Therapeutics Holding SA
About the publication
12 May 2023 11:45PM
Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
CH0100191136
Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission GENEVA (May 12, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFFD and RLFTD) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for t...
Relief Therapeutics Holding SA
About the publication
12 May 2023 11:45PM
Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
CH0100191136
Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission GENEVA (May 12, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFFD and RLFTD) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for t...
Relief Therapeutics Holding SA
About the publication
03 May 2023 07:00AM
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
CH0100191136
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares 03.05.2023 / 07:00 CET/CEST Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares GENEVA (May 3, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: ...
Relief Therapeutics Holding SA
About the publication
03 May 2023 07:00AM
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
CH0100191136
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares 03.05.2023 / 07:00 CET/CEST Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares GENEVA (May 3, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: ...
Relief Therapeutics Holding SA
About the publication
01 May 2023 07:00AM
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
CH0100191136
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule  Acer reports OLPRUVA™ drug availability anticipated in mid-June 2023; Acer is engaged in discussions with payers representing a substantial majority of covered lives; 70 percent of metabolic treatment providers surveyed by Acer at ...
Relief Therapeutics Holding SA
About the publication
01 May 2023 07:00AM
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
CH0100191136
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule  Acer reports OLPRUVA™ drug availability anticipated in mid-June 2023; Acer is engaged in discussions with payers representing a substantial majority of covered lives; 70 percent of metabolic treatment providers surveyed by Acer at ...
Relief Therapeutics Holding SA
About the publication
28 April 2023 07:00PM
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
CH0100191136
Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders 28.04.2023 / 19:00 CET/CEST Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders Shareholders approved all proposals by a large majority; Company to effectu...
Relief Therapeutics Holding SA
About the publication
28 April 2023 07:00PM
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
CH0100191136
Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders 28.04.2023 / 19:00 CET/CEST Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders Shareholders approved all proposals by a large majority; Company to effectu...
Relief Therapeutics Holding SA
About the publication
17 April 2023 07:00AM
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
CH0100191136
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100® (Aviptadil Acetate) Relief to file a revised provisional patent application for RLF-100® based on the new stability results GENEVA (April 17, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeuti...
Relief Therapeutics Holding SA
About the publication
17 April 2023 07:00AM
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
CH0100191136
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100® (Aviptadil Acetate) Relief to file a revised provisional patent application for RLF-100® based on the new stability results GENEVA (April 17, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeuti...
Relief Therapeutics Holding SA
About the publication
14 April 2023 07:00AM
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
CH0100191136
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update   GENEVA, April 14, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or Relief), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to b...
Relief Therapeutics Holding SA
About the publication
14 April 2023 07:00AM
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
CH0100191136
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update   GENEVA, April 14, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or Relief), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to b...
Relief Therapeutics Holding SA
About the publication
05 April 2023 07:00AM
Relief Therapeutics Announces Executive Leadership Team Change
CH0100191136
Relief Therapeutics Announces Executive Leadership Team Change GENEVA, APRIL 5, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company committed to advancing treatment paradigms to benefit the lives of patients living with rare diseases, today announced that Nerme...
Relief Therapeutics Holding SA
About the publication
05 April 2023 07:00AM
Relief Therapeutics Announces Executive Leadership Team Change
CH0100191136
Relief Therapeutics Announces Executive Leadership Team Change GENEVA, APRIL 5, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company committed to advancing treatment paradigms to benefit the lives of patients living with rare diseases, today announced that Nerme...
Relief Therapeutics Holding SA
About the publication
04 April 2023 07:00AM
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
CH0100191136
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders  Proposes a reverse stock split of its ordinary shares in preparation for planned listing to the Nasdaq Stock Market   GENEVA, APRIL 4, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief Therapeutics" or the "Company"), a biopharmaceut...
Relief Therapeutics Holding SA
About the publication
04 April 2023 07:00AM
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
CH0100191136
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders  Proposes a reverse stock split of its ordinary shares in preparation for planned listing to the Nasdaq Stock Market   GENEVA, APRIL 4, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief Therapeutics" or the "Company"), a biopharmaceut...
Relief Therapeutics Holding SA
About the publication
03 April 2023 07:00AM
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
CH0100191136
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board Dr. Gao has made foundational contributions in the discovery and characterization of adeno-associated virus (AAV) serotypes which were instrumental in the resurgence of gene therapy GENEVA, APRIL 3, 2023 – RELIEF THERAPEUTIC...
Relief Therapeutics Holding SA
About the publication
03 April 2023 07:00AM
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
CH0100191136
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board Dr. Gao has made foundational contributions in the discovery and characterization of adeno-associated virus (AAV) serotypes which were instrumental in the resurgence of gene therapy GENEVA, APRIL 3, 2023 – RELIEF THERAPEUTIC...
Relief Therapeutics Holding SA
About the publication
22 March 2023 07:00AM
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
CH0100191136
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023 Acer Therapeutics reports data from a survey of UCD healthcare providers show taste and odor are the most important attributes when considering treatment options and adherence  GENEVA, March 2...
Relief Therapeutics Holding SA
About the publication
22 March 2023 07:00AM
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
CH0100191136
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023 Acer Therapeutics reports data from a survey of UCD healthcare providers show taste and odor are the most important attributes when considering treatment options and adherence  GENEVA, March 2...
Relief Therapeutics Holding SA
About the publication
More Relief Therapeutics Holding SA related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN